Bacterial Toxin Fusion Proteins Elicit Mucosal Immunity against a Foot-and-Mouth Disease Virus Antigen When Administered Intranasally to Guinea Pigs

Table 1

Vaccination strategy for guinea pig experiment.

Group	Priming week	Boosting week	Route	Dose	Treatment
I	0	1,2,4	i.n.	100 μg	OVA
II	0	1,2,4	i.n.	100 μg	TCA Peptide
III	0	1,2,4	i.n.	100 μg	LTA2B-GH
IV	0	1,2,4	i.n.	100 μg	ntPE-LTA2B-GH
V	0	3	s.c.	100 μg	OVA
VI	0	3	s.c.	100 μg	TCA Peptide
VII	0	3	s.c.	100 μg	LTA2B-GH
VIII	0	3	s.c.	100 μg	ntPE-LTA2B-GH